The use of standardised infusion concentrations offers several significant benefits, including an opportunity to develop licensed, ready-to-administer formulations, such as pre-filled syringes, which can eliminate the known risks and inconsistencies associated with ward-level preparation while also saving nursing time.
Standardisation also enables the creation of a national “smart pump” drug library, reduces variation in practice between centres, ensures continuity of care during patient transfers, enhances familiarity for staff rotating between hospitals and facilitates “closed loop” medication processes.
The standardised infusion framework is becoming increasingly embedded in practice nationally, including in all neonatal units in the East of England and ongoing roll out in other neonatal networks. All practitioners and providers of care to children and young people, as well as national organisations committed to improve safety of medicines in children, are encouraged to review and implement the recommendations in the framework.
The original framework was updated in 2024 to included recommendations for patients weighing under 2kg, and a further update is now published in November 2026. The most recent update introduces standardised concentrations for dexmedetomidine and includes changes to reflect the fact that a licensed, ready to use dopamine product is now available. It is recognised that changes to the framework can be challenging to implement in those centres which already have standardised concentration infusions embedded; as such immediate implementation may not be possible, but centres are nonetheless encouraged to adopt the new concentrations at the earliest opportunity.
If you have any questions about the standardised infusion framework, please contact standardinfusions@nppg.org.uk